Online Registry Improves Clinical Research Study Participation
LOS ANGELES (July 13, 2015) - Research for Her™, Cedars-Sinai's groundbreaking online registry that matches women with research studies and clinical trials, enrolled study participants more quickly when compared with traditional paper-based registries, according to new research published in the journal Gynecologic Oncology.
Historically, fewer women have participated in clinical research and only 3 to 5 percent of patients nationally enroll in trials.
"Research for Her is committed to changing these statistics and improving patient lives," saidB.J. Rimel, MD, co-principal investigator of Research for Her, part of the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, and first author of the study.
A total of 322 women were enrolled in the Cedars-Sinai Research for Her registry over a 14-month period - a 4.3 fold increase over the paper-based registry. Of these 322 women, 263 were matched to at least one study and of those, 39 eligible individuals went on to enroll. The enrollment process increased in speed by 27 percent.
The Research for Her registry also spurred a 50 percent increase in enrollments for the Gilda Radner Hereditary Cancer Program, part of the Women's Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in 2014. Founded in 1991, the Gilda Radner program consists of several research studies for women at higher risk for breast and ovarian cancer.
Research for Her, created in 2013, is currently open to all women over the age of 18 with or without a prior history of cancer. It soon will expand to also enroll and link men to available clinical trials or research studies at Cedars-Sinai.
"The early successes of Research for Her are encouraging," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and the Phase One Foundation Chair. "We are eager to continue fostering the program's growth and potential, while bolstering patient lives."
Next steps also include identifying innovative methods to capture complex data from patients - such as molecular tumor profiling - to further decrease the time to enrollment for studies and provide more comprehensive prescreening for patients.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
